GSK’s share value has seen volatility recently, with a significant drop of 15%. Despite this, the company managed to trade green for seven consecutive sessions. A key factor causing the drop is the legal setback regarding Zantac and the subsequent approval of lawsuits against the company. However, the company has tried to rebound the situation by increasing the dividends, hinting that it's an attractive addition to portfolios. The execs are putting their skin in the game by purchasing more shares through dividend reinvestment. GSK's value has raised as they expanded their vaccine portfolio, partnering with CureVac to develop COVID-19 and flu vaccines. There are speculations that GSK might bounce back to its 2022 high of $47 despite recent lawsuits and vaccine disappointments. It also increased its 2024 outlook based on its strong growth in key drugs and vaccines. This update came even after the sales from their top two vaccines underperformed expectations. Also, GSK successfully completed a $1.56 bn deal with CureVac, adding further value to the company.
GSK Stocks News Analytics from Wed, 17 Jan 2024 08:00:00 GMT to Mon, 26 Aug 2024 01:53:28 GMT -
Rating -4
- Innovation 2
- Information 8
- Rumor -6
